The Biotech Investor
How to Profit from the Coming Boom in Biotechnology
Versandkostenfrei!
Versandfertig in 1-2 Wochen
20,99 €
inkl. MwSt.
PAYBACK Punkte
10 °P sammeln!
"Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner." -Thom Calandra, editor in chief, CBS MarketWatch In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry. Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies f...
"Tom Abate's reporting on biotechnology has always been ahead of the times. The Biotech Investor tackles the brave new world of stem cells, genomics, and clones and comes up a winner." -Thom Calandra, editor in chief, CBS MarketWatch In The Biotech Investor, San Francisco Chronicle biotechnology reporter Tom Abate explains the science, finances, time horizon, and technological and commercial potential of this burgeoning industry. Abate provides guidelines for assessing company leadership, easy-to-digest reports from the labs, and indispensable investor tools and metrics. He shares strategies for . tracking the effect of breaking news and the NASDAQ . anticipating drug trial announcements and FDA approvals . assessing the potential market, patent rights, and distribution deals for a drug He looks beyond medicine to biotech-related opportunities in everything from agriculture to jean manufacturing to software development. The Biotech Investor is the comprehensive, expert source for successful and intelligent investing in one of the twenty-first century's most promising industries.
